-
-
-
-
-
-
-
I-Mab Reports Third Quarter 2024 Results
-
-
-
-
-
-
-
I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates
-
-
-
-
-
-
-
TRACON Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating, $95 Price Target on I-Mab (IMAB), Expects "Greater Appreciation for the Company's Pipeline"
-
-
-
-
-
-
-
AbbVie Reports Full-Year and Fourth-Quarter 2021 Financial Results
-
-
-
-
-
-
-
ProMIS Neurosciences Announces First Quarter 2021 Results
-
-
-
-
-
-
-
I-Mab Reports Financial Results for the Six Months Ended June 30 and Provides Corporate Update
-
1,197,524 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

